Croda International PLC - Yorkshire, England-based chemicals maker - Says its recent ‘strong’ organic growth from its drug delivery platforms - excluding its Covid-19 lipid systems - has continued. Sees its ‘exciting innovation’ pipeline hitting commercialisation from 2025. The platform sits within its Health Care business, which forms part of the firm’s Life Sciences unit.

Chief Executive Steve Foots says: ‘Over the last twenty years, we have been steadily growing and investing in our Health Care business, accelerating this progress with the acquisitions of vaccine adjuvant and lipid system technologies.

‘Today we are focused on robust, high growth and high value markets, uniquely positioned as the leading innovator of delivery systems for complex biologic drugs and vaccines. It is an exciting part of Croda with significant opportunities to drive future growth.’

Current stock price: 6,672.00 pence

12-month change: down 20%

Copyright 2022 Alliance News Limited. All Rights Reserved.